www.fdanews.com/articles/188103-kleresca-approved-in-eu-for-dermatological-platform
![Grey Approved Stamp](https://www.fdanews.com/ext/resources/test/Drug-Images4/Grey_Approved_Stamp.gif?t=1576541258&width=430)
Kleresca Approved in EU for Dermatological Platform
August 21, 2018
Dermatological device developer Kleresca gained a CE Mark for its biophotonic dermatological system.
The device uses a non-invasive fluorescent light treatment to encourage the skin’s biological processes, repair skin in patients and treat rosacea. It can also be used as an add-on treatment for other dermatological procedures, such as laser treatments.
The device cannot cause a photosensitive reaction because the treatment gel is not absorbed by the skin, and the treatment does not damage the skin’s natural barriers.